NRx Pharmaceuticals (NASDAQ:NRXP) versus Nanobiotix (NASDAQ:NBTX) Head to Head Survey

NRx Pharmaceuticals (NASDAQ:NRXP) and Nanobiotix (NASDAQ:NBTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations for NRx Pharmaceuticals and Nanobiotix, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	1	1	4	0	2.50
Nanobiotix	1	0	4	0	2.60

NRx Pharmaceuticals currently has a consensus price target of $38.00, suggesting a potential upside of 1,420.00%. Nanobiotix has a consensus price target of $25.00, suggesting a potential downside of 21.46%. Given NRx Pharmaceuticals’ higher probable upside, equities research analysts plainly believe NRx Pharmaceuticals is more favorable than Nanobiotix.

Risk & Volatility

NRx Pharmaceuticals has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500. Comparatively, Nanobiotix has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500.

Profitability

This table compares NRx Pharmaceuticals and Nanobiotix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	N/A	N/A	-265.03%
Nanobiotix	N/A	N/A	N/A

Valuation & Earnings

This table compares NRx Pharmaceuticals and Nanobiotix”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23 million	67.22	-$28.62 million	($1.39)	-1.80
Nanobiotix	$36.87 million	41.79	-$27.11 million	N/A	N/A

Nanobiotix has higher revenue and earnings than NRx Pharmaceuticals.

Insider & Institutional Ownership

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 38.8% of Nanobiotix shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by company insiders. Comparatively, 3.5% of Nanobiotix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Nanobiotix beats NRx Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

About Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.